| 摘要: |
| [摘要]目的：探讨中枢性性早熟（CPP）女孩安全、有效的治疗方法。方法：选择2013年10月至2017年10月同济医院收治的CPP女孩34例，按照随机对照方法分为研究组19例和对照组15例。研究组使用醋酸亮丙瑞林+生长激素治疗，对照组使用醋酸亮丙瑞林治疗，比较两组患儿治疗24个月后黄体生成素（LH）峰值和LH峰值/卵泡刺激素（FSH）峰值抑制至青春期前水平的受试者比例，预测成人身高（PAH）较基线有改善的受试者比例以及改善情况，比较两组患儿治疗前后空腹血糖（FPG）、胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）水平以及不良反应发生情况。结果：治疗24个月后，对照组和研究组LH峰值受到抑制的受试者比例均为100%，LH峰值/FSH峰值受到抑制的受试者比例分别为100%、94.74%；PAH与基线相比有改善的受试者比例均为100%，PAH从治疗前到24个月后的平均值（SD）变化分别为（14.00±0.79）cm、（17.00±1.12）cm。治疗前后两组患儿FPG、TC、TG、HDL-C、LDL-C比较差异均无统计学意义（P均>0.05）。两组分别报告了4例和5例不良反应，均为轻中度。结论：两组CPP女孩接受治疗后，PAH均明显高于基线时的PAH，研究组PAH较对照组略有升高，但是差异无统计学意义。两组不良反应发生率均较低，均为轻中度。 |
| 关键词: 醋酸亮丙瑞林 生长激素 预测成人身高 中枢性性早熟 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2020.09.004 |
|
| 基金项目: |
|
| Efficacy and Safety of Leuprolide Acetate Combined with Growth Hormone in the Treatment of Girls with Central Precocious Puberty |
| Chu Wei1,2, Zhang Cai1, Shen Yuxia2, Luo Xiaoping1 |
| (1. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan 430030, China; 2. Affiliated Hospital of Anhui Clinical Research Center of Traditional Chinese Medicine, Anhui Hefei 230000, China) |
| Abstract: |
| [Abstract] Objective: To probe into the safe and effective treatment methods for girls with central precocious puberty (CPP). Methods: Totally 34 girls with CPP admitted into Tongji Hospital from Oct. 2013 to Oct. 2017 were extracted to be divided into the study group and the control group via the random number table, with 19 cases in each group. The study group was treated with leuprolide acetate + growth hormone, and the control group received leuprolide acetate. Proportion of subjects with peak luteinizing hormone (LH) suppression, and peak LH/peak follicle stimulating hormone (FSH) suppression to prepubertal levels, proportion of subjects with an improvement in predicted adult height (PAH) from baseline of two groups were compared after treatment of 24 months. Fasting blood glucose (FPG), cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) levels and the incidence of of adverse drug reactions of two groups were observed. Results: After treatment of 24 months, the proportions of subjects with peak LH suppression in two groups were 100%. The proportions of subjects with peak LH/peak FSH suppression to prepubertal levels in the control group and the study group were respectively 100% and 94.74%. The proportion of subjects with improvement of PAH compared with baseline was 100%. The mean (SD) changes of PAH from before treatment to 24 months after treatment were (14.00±0.79) cm and (17.00±1.12) cm, respectively. There was no significant difference in FPG, TC, TG, HDL-C and LDL-C between two groups before and after treatment (P>0.05). Adverse drug reactions were reported in 4 and 5 cases in two groups, which were mild and moderate. Conclusion: After treatment for two group of girls with CPP, the PAH was significantly higher than that of the baseline. The PAH of the study group was slightly higher than that of the control group, yet the difference was not statistically significant. The incidence of adverse drug reactions in both groups was relatively low, all of which were mild and moderate. |
| Key words: leuprorelin acetate growth hormone predicted adult height central precocious puberty |
